Soon after her diagnosis, Storm’s physician team ordered PreludeDx’s DCISionRT®, the only risk assessment test that predicts radiation therapy (RT) benefit in DCIS patients, to be run on her tumor ...

December 10, 2010 (San Antonio, Texas) — "Nobody knows whether patients with HER2-positive ductal carcinoma in situ (DCIS) have increased local recurrence of disease," said Lia Halasz, MD, a radiation ...

LAGUNA HILLS, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced study ...

Delaying radiation therapy too long after surgery significantly increases the risk of recurrent tumors in women treated for very early, or what is referred to as "stage 0," breast cancer, according to ...

DCIS, often called Stage Zero breast cancer, is the earliest stage and often diagnosed via mammogram, with no symptoms. In most cases, DCIS will not turn into a life-threatening tumor, but doctors ...

A newly released study is challenging the way doctors commonly treat patients with ductal carcinoma in situ (DCIS), known as stage zero breast cancer. DCIS cancer cells are confined inside a milk duct ...

Improving patient understanding of GEP test results (IMPARTER4): An RCT. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text component.

LAGUNA HILLS, Calif., Feb. 22, 2024 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that data ...

Breast cancer is not a single disease but multiple ones, each carrying varying degrees of risk for endangering women’s health. In recent years, many researchers have been focused on DCIS: ductal ...

NEW YORK (Reuters Health) - A review of published studies confirms that the addition of radiation therapy to breast-conserving surgery in the treatment of a noninvasive early form of breast cancer ...

LAGUNA HILLS, Calif., Feb. 12, 2025 /PRNewswire/ — Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced a partnership with Hannah Storm, ...